Rubius Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2016 to 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Rubius Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2016 to 2022.
  • Rubius Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2022 was -$23.1M, a 57% increase year-over-year.
  • Rubius Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2022 was -$178M, a 8.31% increase year-over-year.
  • Rubius Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$178M, a 8.31% increase from 2021.
  • Rubius Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$195M, a 16.9% decline from 2020.
  • Rubius Therapeutics, Inc. annual Operating Income (Loss) for 2020 was -$166M, a 1.86% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$178M +$16.2M +8.31% Jan 1, 2022 Dec 31, 2022 10-K 2023-02-27
2021 -$195M -$28.2M -16.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-27
2020 -$166M +$3.15M +1.86% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 -$170M -$77.9M -85% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-25
2018 -$91.7M -$48.4M -112% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-23
2017 -$43.3M -$32.4M -299% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 -$10.9M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.